Adagene Inc. has announced a strategic partnership with ConjugateBio Inc. to advance the development of novel antibody drug conjugates (ADCs). As part of the agreement, Adagene will supply a proprietary antibody for ConjugateBio's bispecific ADC programs. In return, Adagene will receive an undisclosed upfront payment, along with milestone and royalty payments, while retaining all non-ADC rights to the antibody. This collaboration aims to leverage Adagene's distinguished antibody discovery capabilities and ConjugateBio's expertise in ADC development, potentially expanding the ADC market, which is projected to exceed $30 billion by 2030.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9489002-en) on July 08, 2025, and is solely responsible for the information contained therein.